FDA approves AstraZeneca's once-weekly Klygefa for generalised myasthenia gravis
Alexion, AstraZeneca's rare disease arm, won FDA approval for Klygefa (gefurulimab) in adults with anti-AChR antibody-positive generalised myasthenia gravis. It's the first dual-binding nanobody C5 inhibitor patients can self-inject once a week, backed by Phase III PREVAIL data showing improvement by week 26 and as early as week one.
- Original source: biobuzz.io.
- The source published it on Nov 19, 2026 at 7:03 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA has cleared Klygefa (gefurulimab) for adults with generalised myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, Alexion announced. The AstraZeneca rare disease unit calls it the first and only dual-binding nanobody C5 inhibitor — and the first in this class patients can give themselves once a week through an autoinjector.
The green light rests on the pivotal PREVAIL Phase III trial, which put 260 patients across 20 countries on Klygefa or placebo for 26 weeks. Klygefa hit its primary endpoint on the Myasthenia Gravis Activities of Daily Living score, with a treatment difference of -1.6 versus placebo (95% CI: -2.4, -0.8, p<0.0001). Investigators also saw clinical improvement as early as week one.
Kelly Gwathmey, a neuromuscular neurologist at Columbia University and principal investigator at Virginia Commonwealth University, said the trial delivered on two fronts: rapid and sustained functional improvement, plus a once-weekly self-administered shot. She framed the approval as giving US patients a targeted option that builds in greater autonomy.
Tolerability tracked with earlier C5 inhibitors eculizumab and ravulizumab, Alexion said — treatment-emergent adverse events came in at similar rates to placebo and were mostly grade 1 or 2. The most common in the Klygefa arm were injection site reactions at 12%, back pain at 8% and vomiting at 5%. The PREVAIL data were presented at the MGFA Scientific Session during the AANEM 2025 Annual Meeting and published in JAMA Neurology.
Myasthenia Gravis Foundation of America CEO Samantha Masterson welcomed the news as a matter of choice, noting no two patients experience gMG the same way and that more options help those seeking independence in managing their treatment. Alexion CEO Marc Dunoyer said the company looks forward to delivering the drug to US adults with gMG soon.
The market is sizeable for a rare disease: an estimated 98,500 people in the US are diagnosed with gMG, 81,000 of them AChR-positive. Klygefa is already approved in the EU, Japan and other countries, with regulatory submissions based on PREVAIL still under review in China and elsewhere.
TopicsAstraZeneca · Alexion · Klygefa · gefurulimab · FDA · Myasthenia Gravis Foundation of America · Marc Dunoyer · Kelly Gwathmey
Source: biobuzz.io
Written by AI from verified reporting.
More stories
- Health & science wired.com 0 viewsEl Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following
- Health & science theguardian.com 1 viewPancreatic cancer pill erases tumours in 1 in 12 patients, trial finds
- Health & science pluang.com 1 viewGalleri wins FDA panel nod as GRAIL chases first multi-cancer screening approval
- Health & science techtimes.com 2 sources 2 viewsFDA Clears Regeneron's Quarterly RNA Shot Livsayis for Myasthenia Gravis

